STRUCTURAL STUDIES OF THE HIGH AFFINITY IGE RECEPTOR
高亲和力 IGE 受体的结构研究
基本信息
- 批准号:2429490
- 负责人:
- 金额:$ 18.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-06-01 至 2001-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Many hematopoietic cells express cell-surface receptors that distinguish
antibody classes (e.g. IgE or IgG) through interactions with the antibody-
Fc regions. The expression of these Fc receptors on many different cell
types couples the diversity of the antibody response to cell-mediated
immune mechanisms that include cytotoxic, degranulatory, and phagocytic
reactions. Fc receptors specific for IgE and IgE and IgG fall into a
common structural class with homologous extracellular immunoglobulin
domains that are responsible for antibody binding. Antigen antibody
complexes trigger the aggregation of Fc receptors and thereby activate
cells, using signaling pathways that are analogous to those of the T and B
cell receptor. Little is known about the specific structural interactions
that govern the recognition of antibody classes by different Fc receptors
or the subsequent signaling complexes that are formed.
The goal of this proposal is to understand in atomic detail how Fc
receptors discriminate between antibody molecules and to determine what
role conformational changes may have in regulating binding or signaling of
these receptors. In order to address these questions we have chosen to
study the high affinity IgE-Fc receptor (Fcepsilon RI) from mast cells.
The FcepsilonRI is important in triggering immediate-type
hypersensitivities such as common allergic diseases and anaphylactic shock.
The specific aims this proposal are to (1) determine the structure of the
FcepsilonRI by X-ray crystallography and (2) to determine the
crystallographic structures of the IgE-Fc region alone and in a complex
with FcepsilonRI. We have initial crystals of the extracellular region of
the Fcepsilon RI that binds antibody. In addition, Fc-fragments of the IgE
molecule are being generated and will be used for further crystallization
experiments. The three proposed structures will clarify at the atomic
level the interaction of Fc receptor with antibody and may lead to new
approaches for the treatment of allergy, arthritis, and antibody-mediated
tumor immunity.
许多造血细胞表达细胞表面受体,这些受体可以区分
通过与抗体相互作用而产生的抗体类别(例如,IgE或IgG)-
FC区域。这些Fc受体在多种不同细胞上的表达
不同类型的抗体对细胞介导的反应不同
免疫机制包括细胞毒性、脱粒细胞和吞噬
反应。Ig E和Ig E和Ig G特异性Fc受体落入
具有同源细胞外免疫球蛋白的共同结构类
负责抗体结合的结构域。抗原抗体
复合体触发Fc受体的聚集,从而激活
细胞,使用与T和B相似的信号通路
细胞受体。对具体的结构相互作用知之甚少。
管理不同Fc受体对抗体类别的识别
或随后形成的信号复合体。
这项建议的目标是详细了解FC如何
受体区分抗体分子并确定
构象变化可能在调节结合或信号转导中起作用
这些受体。为了解决这些问题,我们选择了
肥大细胞高亲和力IgE-Fc受体(Fcepsilon RI)的研究
FcepsilonRI在触发即时型中很重要
过敏反应,如常见的过敏性疾病和过敏性休克。
这项建议的具体目的是:(1)确定
用X射线结晶学和(2)测定Fcepsilon RI。
IgE-Fc区单独和复合体的晶体结构
和FcepsilonRI一起。我们已经有了胞外区的初始晶体
结合抗体的Fcepsilon RI。此外,免疫球蛋白E的Fc片段
分子正在生成,并将用于进一步的结晶
实验。三个拟议的结构将在原子会议上澄清
Fc受体与抗体的相互作用并可能导致新的
变态反应、关节炎和抗体介导的治疗方法
肿瘤免疫。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Theodore S Jardetzky其他文献
Theodore S Jardetzky的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Theodore S Jardetzky', 18)}}的其他基金
Discovery and engineering of novel anti-IgE disruptive inhibitors
新型抗 IgE 破坏性抑制剂的发现和工程设计
- 批准号:
10353982 - 财政年份:2021
- 资助金额:
$ 18.2万 - 项目类别:
Discovery and engineering of novel anti-IgE disruptive inhibitors
新型抗 IgE 破坏性抑制剂的发现和工程设计
- 批准号:
10495213 - 财政年份:2021
- 资助金额:
$ 18.2万 - 项目类别:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
五聚体和三聚体复合物介导的人巨细胞病毒进入细胞
- 批准号:
10468251 - 财政年份:2020
- 资助金额:
$ 18.2万 - 项目类别:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
五聚体和三聚体复合物介导的人巨细胞病毒进入细胞
- 批准号:
10687819 - 财政年份:2020
- 资助金额:
$ 18.2万 - 项目类别:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
五聚体和三聚体复合物介导的人巨细胞病毒进入细胞
- 批准号:
10120270 - 财政年份:2020
- 资助金额:
$ 18.2万 - 项目类别:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
五聚体和三聚体复合物介导的人巨细胞病毒进入细胞
- 批准号:
10265549 - 财政年份:2020
- 资助金额:
$ 18.2万 - 项目类别:
Repertoire studies of human antibodies to RSV and MPV F
RSV 和 MPV F 人类抗体的谱研究
- 批准号:
10249184 - 财政年份:2018
- 资助金额:
$ 18.2万 - 项目类别:
Suppression of basophil activation by IgE glycovariants
IgE 糖变体抑制嗜碱性粒细胞活化
- 批准号:
9900056 - 财政年份:2018
- 资助金额:
$ 18.2万 - 项目类别:
相似海外基金
Study on the mechanism of prolonged half-life of blood IgY by unique antibody receptor and its application to immune enhancement in birds
独特抗体受体延长血液IgY半衰期的机制研究及其在禽类免疫增强中的应用
- 批准号:
23H02361 - 财政年份:2023
- 资助金额:
$ 18.2万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
- 批准号:
nhmrc : GNT1124162 - 财政年份:2017
- 资助金额:
$ 18.2万 - 项目类别:
Early Career Fellowships
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
- 批准号:
nhmrc : 1124162 - 财政年份:2017
- 资助金额:
$ 18.2万 - 项目类别:
Early Career Fellowships
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
- 批准号:
9300976 - 财政年份:2015
- 资助金额:
$ 18.2万 - 项目类别:
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
- 批准号:
9920805 - 财政年份:2015
- 资助金额:
$ 18.2万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8900121 - 财政年份:2012
- 资助金额:
$ 18.2万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8225814 - 财政年份:2012
- 资助金额:
$ 18.2万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8699511 - 财政年份:2012
- 资助金额:
$ 18.2万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8525355 - 财政年份:2012
- 资助金额:
$ 18.2万 - 项目类别:
Small Grants for Exploratory Research: Separation of Cells and Biological Macromolecules by Antibody Receptor Coated Magnetic Vesicles and Ferritin Conjugates
探索性研究小额资助:通过抗体受体包被的磁囊和铁蛋白缀合物分离细胞和生物大分子
- 批准号:
9115537 - 财政年份:1991
- 资助金额:
$ 18.2万 - 项目类别:
Standard Grant